Watson Pharma (WPI) Reports Changes to Executive Team Following Actavis Acquisition

April 27, 2012 9:06 AM EDT
Watson Pharmaceuticals, Inc. (NYSE: WPI) has refined and expanded the responsibilities of its senior executive team, in recognition of the Company's continued global expansion, particularly following the announcement of Watson's intention to acquire Actavis.

The Company announced the following changes in management structure. Sigurdur Oli Olafsson, Executive Vice President, Global Generics, has been named President of Global Generics. G. Frederick Wilkinson, Executive Vice President of Global Brands, has been named President, Global Brands and Biosimilars. Robert A. Stewart, Executive Vice President, Global Operations, will assume expanded responsibilities leading the Company's Anda, Inc. distribution business, and has been named President, Global Operations. Additionally, David A. Buchen has been named Chief Legal Officer - Global; R. Todd Joyce has been named Chief Financial Officer- Global; Charles M. Mayr has been named Chief Communications Officer – Global; and Patrick J. Eagan has been named Senior Vice President, Human Resources - Global. These changes reflect their broader global responsibilities as the proposed acquisition of Actavis progresses.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Management Changes, Mergers and Acquisitions